Progressive ataxic gait disorder

Journal of Clinical Neuroscience

Volumn 14, Issue 2, 2007, Pages 153-157

  Rupasinghe, Jayantha ^a   Butler, Ernest ^a  

^a FRANKSTON HOSPITAL   (Australia)

Author keywords

Adenocarcinoma; Anti Yo antibodies; CERB 2; Paraneoplastic cerebellar degeneration

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; MEPREDNISONE; TRASTUZUMAB; YO ANTIBODY;

ADENOCARCINOMA; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CASE REPORT; CEREBELLAR ATAXIA; CEREBELLUM; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAMMOGRAPHY; MICROSCOPY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DIFFERENTIATION;

ADENOCARCINOMA; CEREBELLAR DISEASES; FEMALE; GAIT ATAXIA; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PARANEOPLASTIC CEREBELLAR DEGENERATION; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 33845310876     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2005.11.037     Document Type: Article

References (17)

1. Clouston P.D., DeAngelis L.M., and Posner J.B. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 31 (1992) 268-273
2. Dropcho E.J. The remote effects of cancer on the nervous system. Neurol Clin 7 (1989) 579-603
3. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Efficacy and safety of herceptin (humanized antiHER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17 (1998) 97A Abstract 376
4. Salmon D., Leyland-Jones B., Shak S., et al. Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17 (1998) 98A Abstract 377
5. Posner J.B. Paraneoplastic syndromes. Neurologic complications of systemic cancer. Neurol Clin 9 (1991) 919-936
6. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, therapy. Lancet 1 (2002) 294-305
7. Liu S., Tunkel R., Lachmann E., et al. Paraneoplastic cerebellar degeneration as the first evidence of cancer. A case report. Arch Phys Med Rehabil 81 (2000) 834-836
8. Rojas J., Graus F., Keime Guibert F., et al. Long term clinical outcome of paraneoplastic cerebellar degeneration and anti Yo antibodies. Neurology 55 (2000) 713-715
9. Hainsworth J.D., Lennigton W.J., and Greco F.A. Over expression of HER 2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18 (2000) 632
10. Peterson K., Rosenblum M.K., Kotanides H., et al. Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology 42 (1992) 1931-1937
11. Mehdi A, Ko DY. Paraneoplastic cerebellar degeneration. eMedicine Neurology Topic 299. Omaha, NE: eMedicine.com; updated March 21, 2006. Available at: http://www.emedicine.com/neuro/topic299.htm. Accessed June 2, 2006.
12. David Y.B., Warner E., Leviton M., et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 78 (1996) 2153-2156
13. Cher L.M., Hochberg F.H., Teruya J., et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 75 (1995) 1678-1683
14. Blaes F., Strittmatter M., Merckelbach S., et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 246 (1999) 299-303
15. Stark E., Wurster U., Patzold U., et al. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 52 (1995) 814-818
16. Graus F., Vega F., Delattre J.Y., et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 42 (1992) 536-540
17. Dalmau J., Gultekin H.S., and Posner J.B. Paraneoplastic neurological syndromes: pathogenensis and physiopathology. Brain Pathol 9 (1999) 275-284